Amgen Inc. (NASDAQ:AMGN) Shares Sold by CarsonAllaria Wealth Management Ltd.

CarsonAllaria Wealth Management Ltd. cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 700 shares of the medical research company’s stock after selling 66 shares during the period. CarsonAllaria Wealth Management Ltd.’s holdings in Amgen were worth $182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the business. Capital Performance Advisors LLP bought a new position in shares of Amgen in the 3rd quarter worth about $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen during the third quarter worth about $29,000. Matrix Trust Co bought a new position in Amgen in the third quarter worth about $36,000. Heck Capital Advisors LLC acquired a new position in Amgen in the fourth quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the third quarter valued at approximately $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.1 %

NASDAQ AMGN opened at $289.02 on Wednesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a market capitalization of $155.36 billion, a P/E ratio of 37.01, a PEG ratio of 2.87 and a beta of 0.56. The company’s 50 day simple moving average is $270.95 and its 200 day simple moving average is $303.82. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Equities research analysts expect that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.29%. Amgen’s dividend payout ratio (DPR) is 115.24%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on AMGN shares. UBS Group cut their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Citigroup lowered their price target on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Piper Sandler cut their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Finally, Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.